COMMUNIQUÉS West-GlobeNewswire

Celcuity Inc. Reports Second Quarter Financial Results and Provides Corporate Update
14/08/2024
Announced plan to initiate Phase 3 VIKTORIA-2 trial evaluating gedatolisib combined with fulvestrant plus a CDK4/6 inhibitor as first-line treatment for patients with HR+, HER2- advanced breast cancer; expect to enroll [...]
Turnstone Biologics Corp. Reports Positive Initial Data from Phase 1 Trial of TIDAL-01 in Metastatic Colorectal Cancer
14/08/2024
Overall response rate (“ORR”) of 25% and 50% disease control rate ("DCR") observed in first four evaluable patients treated with TIDAL-01 with advanced CRC Complete response achieved in heavily pre-treated late line [...]
American Shared Hospital Services Reports Strong Second Quarter 2024 Financial Results
14/08/2024
Revenue increases 27% year over year Reports gain of $3.7 million from strategic acquisition of Rhode Island Radiation Therapy Cancer Centers Now treating patients at the new Puebla, Mexico center Conference Call on [...]
ArriVent BioPharma Reports Second Quarter 2024 Financial Results
14/08/2024
Clinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World [...]
Lyra Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
14/08/2024
– Primary focus continues to be on upcoming results from ENLIGHTEN 1 Phase 3 extension study in 4Q 2024 and ENLIGHTEN 2 pivotal Phase 3 trial in CRS patients in 1H 2025, as planned – – In parallel, the company continues [...]
Tectonic Therapeutic Announces Second Quarter 2024 Financial Results and Recent Business Highlights
14/08/2024
TX45 advances into Phase 2 clinical trial for patients with Group 2 PH-HFpEF with first site activated and screening open in August 2024 Received U.S. Investigational New Drug (IND) clearance for lead program, TX45 in [...]
NeuroOne® Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
14/08/2024
EDEN PRAIRIE, Minn., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and [...]
Arcutis Announces Second Quarter 2024 Financial Results and Provides Business Update
14/08/2024
Second quarter net product revenues for ZORYVE ® franchise of $30.9M, with $17.3M for ZORYVE (roflumilast) cream 0.3%, and $13.6M for ZORYVE (roflumilast) topical foam, 0.3%; sales growth of 547% vs. Q2 '23 and 43% vs. [...]
Silo Pharma Expands Development Agreement with Sever Pharma for Novel Ketamine Implant Therapeutic
14/08/2024
SP-26 dissolvable ketamine-based injectable implant targets chronic pain and fibromyalgia Sever Pharma to scale-up extrusion processes and continue analytical testing for novel non-opioid treatment SARASOTA, FL, Aug. 14 [...]
Decisely Celebrates its Place on the 2024 Inc. 5000 List of Fastest-Growing Private Companies
14/08/2024
ALPHARETTA, GA, Aug. 14, 2024 (GLOBE NEWSWIRE) -- Decisely, a leading provider of health benefits and management solutions for business owners, is proud to announce its inclusion in the prestigious Inc. 5000 list for [...]
SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update
13/08/2024
DENVER, Aug. 13, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (“SeaStar Medical” or the “Company”), a commercial-stage medical device company developing proprietary solutions to reduce the [...]
Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2024
13/08/2024
Guardion Also Provides an Update to Stockholders of Significant Recent Developments HOUSTON, TEXAS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a [...]
Elicio Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
13/08/2024
• AMPLIFY-7P Phase 1 preliminary disease-free (“DFS”) survival demonstrates strong correlation between T cell response and reduced risk of progression or death • AMPLIFY-7P Phase 1 data presented at ASCO demonstrated [...]
Sutro Biopharma Reports Second Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones
13/08/2024
- Sutro will present updated data from the ongoing Phase 1b study of luvelta in combination with bevacizumab in a poster presentation at ESMO 2024; expansion study is ongoing with data expected in the first half of 2025 [...]
BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
13/08/2024
SUNNYVALE, Calif., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported [...]
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
13/08/2024
SAN DIEGO, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) (the Company), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies [...]
Bavarian Nordic Receives Order from HERA and Announces Significant Donation of Vaccines in Response to the Mpox Outbreak in Africa
13/08/2024
HERA will procure 175,420 doses for immediate response to the concerning mpox outbreak in Africa, and furthermore, Bavarian Nordic will donate 40,000 doses to HERA, also to be distributed to the Africa CDC. COPENHAGEN, [...]
Panbela Provides Business Update and Reports Q2 2024 Financial Results
13/08/2024
MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today [...]
SELLAS Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Update
13/08/2024
- Announced Independent Data Monitoring Committee’s (IDMC) Recommendation to Continue the Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Without Modifications: Interim Analysis Anticipated by Q4 2024 [...]

Pages